Nanobac takes option on Calgenex technology

Florida-based Nanobac Pharmaceuticals has signed an agreement with Calgenex granting Nanobac an option to assess fellow US firm Calgenex' drug-delivery technology for potential use with Nanobac's drug combinations used in treating atherosclerosis, prostatitis and other pathologic calcification diseases. The technology includes a novel combination of bisphosphonate and silicic acid.

"Today's option agreement is a testament towards our goal of evaluating the best therapeutic delivery technologies used with our compounds to treat diseases associated with pathologic calcification," commented Alex Edwards, director, of Nanobac, adding: "we will be evaluating the Calgenex technology in the context of our drug development efforts in order to improve on an important class of drugs, namely bisphosphonates."